Kliman David, Bilmon Ian, Kwan John, Blyth Emily, Micklethwaite Ken, Panicker Shyam, Bhattacharyya Abir, Deren Stephanie, Antonenas Vicki, Huang Gillian, Gottlieb David
Blood and Marrow Transplant Unit, Westmead Hospital, Sydney, New South Wales, Australia.
Sydney Cellular Therapies Laboratory, Sydney, New South Wales, Australia.
Intern Med J. 2018 Aug;48(8):988-991. doi: 10.1111/imj.13979.
Graft failure affects approximately 5% of allogeneic stem cell transplants, with a poor prognosis. Salvage second allogeneic stem cell transplantation (alloSCT2) is limited by high rates of transplant-related mortality from infection and graft-versus-host disease. We report on five adult patients receiving rescue alloSCT2 using haploidentical peripheral blood stem cells. All patients achieved neutrophil engraftment, two subsequently died from sepsis and disease relapse, respectively. Three patients remain alive up to 2 years post-transplant. We suggest consideration of haploidentical alloSCT2 for patients with graft failure.
移植物失败影响约5%的异基因干细胞移植，预后较差。挽救性第二次异基因干细胞移植（alloSCT2）受到感染和移植物抗宿主病导致的高移植相关死亡率的限制。我们报告了5例接受单倍体相合外周血干细胞进行挽救性alloSCT2的成年患者。所有患者均实现中性粒细胞植入，其中2例分别随后死于败血症和疾病复发。3例患者移植后存活长达2年。我们建议对移植物失败的患者考虑单倍体相合alloSCT2。
